Actinic keratosis (AKs or solar keratoses) are keratotic macules, papules, or plaques resulting from the intraepidermal proliferation of atypical keratinocytes in response to prolonged exposure to ultraviolet radiation. It's most commonly found on the face, lips, ears, back of your hands, forearms, scalp or neck. LPI (LP Information)' newest research report, the “Actinic Keratosis Treatment Industry Forecast” looks at past sales and reviews total world Actinic Keratosis Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Actinic Keratosis Treatment sales for 2023 through 2029. With Actinic Keratosis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Actinic Keratosis Treatment industry. This Insight Report provides a comprehensive analysis of the global Actinic Keratosis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Actinic Keratosis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Actinic Keratosis Treatment market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Actinic Keratosis Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Actinic Keratosis Treatment. The global Actinic Keratosis Treatment market size is projected to grow from US$ 3240.9 million in 2022 to US$ 4713.9 million in 2029; it is expected to grow at a CAGR of 5.5% from 2023 to 2029. In North America, key companies of actinic keratosis treatment include DUSA Pharmaceuticals, Novartis, Perrigo, LEO Pharma, Bausch Health, Taro Pharmaceutical, Galderma (Nestle), Biofrontera, Almirall and Tolmar Pharmaceutical, etc. As for the types of products, it can be divided into destructive treatment, photodynamic therapy, topical medications and others. The most common product is destructive treatment, with a share over 80%. In terms of applications, it is widely used in hospitals, clinics and others. The most common application is in clinics, with a share over 63%. This report presents a comprehensive overview, market shares, and growth opportunities of Actinic Keratosis Treatment market by product type, application, key players and key regions and countries. Market Segmentation: Segmentation by type Destructive Treatment Photodynamic Therapy Topical Medications Others Segmentation by application Hospital Clinic Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. DUSA Pharmaceuticals Novartis Perrigo LEO Pharma Bausch Health Taro Pharmaceutical Galderma (Nestle) Biofrontera Almirall Tolmar Pharmaceutical
1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Actinic Keratosis Treatment Market Size 2018-2029 2
